<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25000" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Meperidine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Yasaei</surname>
            <given-names>Rama</given-names>
          </name>
          <aff>UCLA Kern Medical</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rosani</surname>
            <given-names>Alan</given-names>
          </name>
          <aff>TTUHSC at the Permian Basin</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Saadabadi</surname>
            <given-names>Abdolreza</given-names>
          </name>
          <aff>Western University/ Kaweah Delta</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rama Yasaei declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Alan Rosani declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abdolreza Saadabadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25000.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Meperidine is in the class of phenylpiperidine as a hydrochloride salt synthetic form of the opioid. Meperidine is used for the treatment of moderate to severe pain. It has intramuscular, subcutaneous, intravenous injection, syrup, and tablet forms. In the 20th century, it was the drug of choice among the opioids in the management of acute pain and the management of some patients with chronic pain. It has also become a drug commonly abused. Meperidine is used as an adjunct to preoperative medications to reduce shivering. This activity outlines the indications, action, and contraindications for meperidine as an analgesic and other related disorders.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of meperidine.</p></list-item><list-item><p>Describe the adverse effects and contraindications of meperidine.</p></list-item><list-item><p>Review the routes of administration of meperidine.</p></list-item><list-item><p>Summarize interprofessional team strategies for improving care coordination and communication to advance the safe use of meperidine and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25000&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25000">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25000.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Meperidine, also known as pethidine, is in the class of phenylpiperidine as a hydrochloride salt synthetic form of the opioid, which is a white crystalline with a melting point of 186 degrees C. This medication has calcium sulfate, dibasic calcium phosphate, starch, stearic acid, and talc as inactive ingredients. Clinicians use meperidine is used for the treatment of moderate to severe pain. It has intramuscular, subcutaneous, intravenous injection, syrup, and tablet forms. In the 20th century, it was the drug of choice amongst the opioids in the management of acute pain by most of the physicians and the management of some patients with chronic pain. Meperidine is also being used as an adjunct to preoperative medications to reduce shivering.<xref ref-type="bibr" rid="article-25000.r1">[1]</xref><xref ref-type="bibr" rid="article-25000.r2">[2]</xref><xref ref-type="bibr" rid="article-25000.r3">[3]</xref></p>
        <p>Meperidine appeared to be safer with a lower risk of addiction when compared to other opioids and because of the anticholinergic effects associated with less biliary spasm or renal colic. However, it appears that risks of addiction, biliary spasm, and renal colic are equal to other opioids. Additionally, due to its toxic metabolite is known as normeperidine, which has serotonergic properties, it correlates with an increased risk of serotonin syndrome and seizure. These issues have led to the removal of meperidine from the World Health Organization&#x02019;s list of essential&#x000a0;medicines, the list of most effective and safe medicines in the health system in 2003.<xref ref-type="bibr" rid="article-25000.r4">[4]</xref><xref ref-type="bibr" rid="article-25000.r5">[5]</xref><xref ref-type="bibr" rid="article-25000.r6">[6]</xref></p>
      </sec>
      <sec id="article-25000.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Meperidine has the same mechanism of action as morphine, which is acting as an agonist to the mu-opioid receptor. The anti-shivering effect may involve the stimulation of k-opioid receptors.<xref ref-type="bibr" rid="article-25000.r7">[7]</xref></p>
        <p>Meperidine also has some local anesthetic effects because of interactions with sodium ion channels. Also, meperidine has stimulant effects by inhibition of the dopamine transporter (DAT) and norepinephrine transporter (NET).</p>
      </sec>
      <sec id="article-25000.s4" sec-type="Administration">
        <title>Administration</title>
        <p><italic toggle="yes">Oral form:&#x000a0;</italic>(not recommended for acute pain control)</p>
        <list list-type="bullet">
          <list-item>
            <p>Tablet form: 50 mg to 100 mg</p>
          </list-item>
          <list-item>
            <p>Syrup form: 50 mg/5 ml</p>
          </list-item>
        </list>
        <p><italic toggle="yes">Injectable solution form:</italic> 25 mg/ml, 50 mg/ml, 75 mg/ml, 100 mg/ml&#x000a0;</p>
        <p><italic toggle="yes">Intravenous (IV) injection:</italic> inject the dose of 10 mg/ml slowly. The injection should be a consideration only when an opiate antagonist and the administration of oxygen and respiratory monitoring facilities are available.</p>
        <p><italic toggle="yes">For continuous IV infusion</italic>: 15 to 35 mg/hr</p>
        <p><italic toggle="yes">Intramuscular:</italic> Injection should be into large muscle mass, and it is preferable to subcutaneous injection.</p>
        <p>Using Meperidine for pain control should be considered if no other options are available, in which case duration of medication use should be limited to less than 48 hours, and the total dosage administered should not exceed 600 mg in 24 hours.</p>
        <p>
<italic toggle="yes">For pain management:</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>In adults: 50 mg to 150 mg orally, IM, subcutaneously (SC) every 3 to 4 hours as needed.</p>
          </list-item>
          <list-item>
            <p>In pediatrics: 1&#x000a0;mg/kg to1.8 mg/kg&#x000a0;orally, IM, subcutaneously (SC) every 3 to 4 hours as needed.&#x000a0;(each dose should not exceed 100mg)</p>
          </list-item>
        </list>
        <p><italic toggle="yes">Continuous infusion:</italic> 15 mg to 35 mg per hour</p>
        <p><italic toggle="yes">Obstetrical pain management:</italic> 50 mg to 100 mg IM/SC,&#x000a0;every 1 to 3 hours as needed</p>
        <p>
<italic toggle="yes">Preoperatively:</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>In adults: 50 mg to 150 mg IM/SC every 3 to 4 hours as needed.</p>
          </list-item>
          <list-item>
            <p>In pediatrics: 1.1&#x000a0;mg/kg&#x000a0;to 2.2 mg/kg SC/IM 30 to 90 minutes before anesthesia</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25000.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Serious Reactions</bold>
</p>
        <p>Shock, seizure, syncope, hallucination (especially among the geriatric population), potential opioid dependency, withdrawal symptoms if discontinued without tapering down, opioid-induced androgen deficiency (chronic use), bradycardia, cardiac arrest, severe hypotension, apnea, respiratory failure.</p>
        <p>
<bold>Common Reactions</bold>
</p>
        <p>Tachycardia, urinary retention, tremor, involuntary movements, xerostomia, constipation, dysphoria, weakness, palpitation, headache, rash, pruritus, urticaria, visual disturbances, involuntary movements, confusion, dysphoria, delirium (especially in geriatric population), nausea, vomiting, lightheadedness, diaphoresis, agitation, orthostatic hypotension, weakness, bradycardia, flushing.</p>
      </sec>
      <sec id="article-25000.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Meperidine is contraindicated in patients that are actively receiving or have been exposed during the past 14 days to monoamine&#x000a0;oxidase inhibitors (MAOI) because of unpredictable severe, and occasionally fatal reactions such as coma, severe respiratory depression, hypotension, cyanosis, and acute narcotic overdose. Also, convulsion, hyper-excitability, tachycardia, hyperpyrexia, and hypertension have been reported. Intravenous hydrocortisone or prednisone have been used to treat severe reactions. In those cases exhibiting hypertension and hyperpyrexia, intravenous chlorpromazine is added.</p>
        <p>Meperidine has respiratory depressant effects and capacity to elevate cerebrospinal fluid pressure especially in patients with head injury or other intracranial lesions. In this group of patients using Meperidine should be with extreme caution. Like other narcotics, using meperidine in patients having an acute asthma attack and chronic obstructive pulmonary disease should be with caution, and these patients should be monitored for any signs of increased airway resistance or apnea.</p>
        <p>Meperidine has several Black Box warnings:</p>
        <list list-type="order">
          <list-item>
            <p>The potential risk of opioid addiction which can cause overdose and death. Physicians should evaluate their patients continuously for developing these conditions.</p>
          </list-item>
          <list-item>
            <p>Life-threatening respiratory failure may occur, therefore monitoring for respiratory depression during the initiation and following dose increase should be considered.</p>
          </list-item>
          <list-item>
            <p>Parallel use with cytochrome P450 3A4 inhibitors or discontinuation of P450 inducers causes the increase of the meperidine concentration that can result in a fatal overdose.</p>
          </list-item>
          <list-item>
            <p>Concomitant use of meperidine and monoamine oxidase inhibitors (MAOI) can cause coma, severe respiratory failure, cyanosis, and hypotension.</p>
          </list-item>
          <list-item>
            <p>Chronic use of meperidine during pregnancy can cause neonatal opioid withdrawal syndrome, which needs to be diagnosed and managed by guidelines of neonatology, which otherwise can be fatal.</p>
          </list-item>
          <list-item>
            <p>Concomitant use of another central nervous system (CNS) depressant like benzodiazepines or alcohol with meperidine may cause profound sedation, respiratory depression, coma, and death.</p>
          </list-item>
          <list-item>
            <p>There is a risk of medication errors, which can be prevented by ensuring accuracy when prescribing, dispensing, and administrating. This is especially important as confusing mg and ml when dosing can result in an accidental fatal overdose.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25000.s7" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Meperidine is a potent opioid analgesic that has the potential for habit-forming and misuse, which increases the risk of overdose.<xref ref-type="bibr" rid="article-25000.r8">[8]</xref><xref ref-type="bibr" rid="article-25000.r4">[4]</xref> Overdose on meperidine happens in:</p>
        <list list-type="bullet">
          <list-item>
            <p>Having an underlying or unknown condition that increases the sensitivity to meperidine</p>
          </list-item>
          <list-item>
            <p>Accidentally or intentionally using more than the prescribed dosage</p>
          </list-item>
          <list-item>
            <p>Concomitant use of meperidine with alcohol, other CNS depressants, or illicit drugs that make changes in the body&#x02019;s sensitivity to the medication.</p>
          </list-item>
        </list>
        <p>The signs of an overdose of meperidine:</p>
        <p>Patients can have shallow or no breathing, signs of cyanosis like blue lips or fingernails, fatigue, convulsion, low blood pressure, bradycardia, constipation, stomach cramps, nausea and vomiting, cold and clammy skin, drowsiness, lightheadedness, and twitching muscles. In severe overdose, patients may experience circulatory relapse, cardiac arrest, apnea, and in some cases, death.</p>
        <p>Treatment of meperidine overdose:</p>
        <p>First, because of potential respiratory failure, the patients&#x02019; airway should be reestablished by ventilation. Then the patient can be managed by activated charcoal to reduce the absorption of the medication in the gastrointestinal (GI) tract by almost 60% (time-dependent). IV fluids are useful for flushing the medication from patients&#x02019; system while balancing&#x000a0;the acid/base equilibrium and minerals of the body. The use of gastric lavage or stomach pumping will wash out the stomach content. Laxatives can be an option to induce defecation to remove the poison from the GI tract. Hemodialysis may help to filter the patient&#x02019;s blood. Administration of opioids antagonists like naloxone to reverse the drug&#x02019;s effects is another means of addressing overdose. Intravenous hydrocortisone or prednisone is also a choice to treat severe reactions. Clinicians can add intravenous chlorpromazine in those cases exhibiting hypertension and hyperpyrexia.</p>
        <p>After the recovery, these patients should participate in addiction treatment programs for the treatment of underlying causes of addiction and support the patient in the process of rehabilitation.</p>
      </sec>
      <sec id="article-25000.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>All healthcare workers, including the pharmacist and nurse practitioner, should be aware that meperidine is no longer considered to be safer than other opiates. It appears that risks of addiction, biliary spasm, and renal colic are equal to other opioids. Additionally, due to its toxic metabolite is known as normeperidine, which has serotonergic properties, it correlates with an increased risk of serotonin syndrome and seizure. This correlation has led to meperidine's removal from the World Health Organization's list of essential&#x000a0;medicines, the list of most effective and safe medicines in the health system in 2003.&#x000a0;</p>
        <p>When prescribed, the patients require close monitoring, and the duration of prescription should not be more than a few days. Experts recommend alternate means of pain control.<xref ref-type="bibr" rid="article-25000.r9">[9]</xref></p>
      </sec>
      <sec id="article-25000.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25000&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25000">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25000/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25000">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25000.s10">
        <title>References</title>
        <ref id="article-25000.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thigpen</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Odle</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Harirforoosh</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Opioids: A Review of Pharmacokinetics and Pharmacodynamics in Neonates, Infants, and Children.</article-title>
            <source>Eur J Drug Metab Pharmacokinet</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>44</volume>
            <issue>5</issue>
            <fpage>591</fpage>
            <page-range>591-609</page-range>
            <pub-id pub-id-type="pmid">31006834</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25000.r2">
          <label>2</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Preuss</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Kalava</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>KC</given-names>
              </name>
            </person-group>
            <chapter-title>Prescription of Controlled Substances: Benefits and Risks</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>4</month>
            <day>29</day>
            <pub-id pub-id-type="pmid">30726003</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25000.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ashley</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Chaudhary</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Louren&#x000e7;o-Matharu</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Sedation of children undergoing dental treatment.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2018</year>
            <month>Dec</month>
            <day>17</day>
            <volume>12</volume>
            <issue>12</issue>
            <fpage>CD003877</fpage>
            <pub-id pub-id-type="pmid">30566228</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25000.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dinges</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Otto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stay</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>B&#x000e4;umlein</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Waldmann</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kranke</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wulf</surname>
                <given-names>HF</given-names>
              </name>
              <name>
                <surname>Eberhart</surname>
                <given-names>LH</given-names>
              </name>
            </person-group>
            <article-title>Side Effect Rates of Opioids in Equianalgesic Doses via Intravenous Patient-Controlled Analgesia: A Systematic Review and Network Meta-analysis.</article-title>
            <source>Anesth Analg</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>129</volume>
            <issue>4</issue>
            <fpage>1153</fpage>
            <page-range>1153-1162</page-range>
            <pub-id pub-id-type="pmid">30418234</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25000.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smischney</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Pollard</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Nookala</surname>
                <given-names>AU</given-names>
              </name>
              <name>
                <surname>Olatoye</surname>
                <given-names>OO</given-names>
              </name>
            </person-group>
            <article-title>Serotonin Syndrome in the Perioperative Setting.</article-title>
            <source>Am J Case Rep</source>
            <year>2018</year>
            <month>Jul</month>
            <day>16</day>
            <volume>19</volume>
            <fpage>833</fpage>
            <page-range>833-835</page-range>
            <pub-id pub-id-type="pmid">30008467</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25000.r6">
          <label>6</label>
          <element-citation publication-type="book">
            <chapter-title>Meperidine</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>12</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000291</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25000.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baldo</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Opioid analgesic drugs and serotonin toxicity (syndrome): mechanisms, animal models, and links to clinical effects.</article-title>
            <source>Arch Toxicol</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>92</volume>
            <issue>8</issue>
            <fpage>2457</fpage>
            <page-range>2457-2473</page-range>
            <pub-id pub-id-type="pmid">29916050</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25000.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raffa</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Pergolizzi</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>LeQuang</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>R</given-names>
              </name>
              <collab>NEMA Research Group</collab>
              <name>
                <surname>Colucci</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Annabi</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>The fentanyl family: A distinguished medical history tainted by abuse.</article-title>
            <source>J Clin Pharm Ther</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>43</volume>
            <issue>1</issue>
            <fpage>154</fpage>
            <page-range>154-158</page-range>
            <pub-id pub-id-type="pmid">28980330</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25000.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Friesen</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Falk</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bugden</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The safety of meperidine prescribing in older adults: A longitudinal population-based study.</article-title>
            <source>BMC Geriatr</source>
            <year>2016</year>
            <month>May</month>
            <day>11</day>
            <volume>16</volume>
            <fpage>100</fpage>
            <pub-id pub-id-type="pmid">27170170</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
